As a novel noninvasive tumor therapy, sonodynamic therapy
(SDT)
attracts booming concerns. However, the limited water solubility,
inadequate biocompatibility, and low targeting ability of conventional
sonosensitizers significantly hinder their potential for clinical
application. Herein, novel zinc(II)-porphyrin nanotheranostics (HA@Zn-TCPP)
were fabricated in which the zinc(II)-porphyrin (TCPP) metal–organic
framework was first constructed by a simple thermal reaction, followed
by the addition of hyaluronic acid (HA) for modification. The specific
targeting ability of HA facilitated the internalization of HA@Zn-TCPP
within tumor cells, resulting in its preferential accumulation in
tumor tissues that exhibit CD44 receptor overexpression. The acidic
tumor microenvironment induced the rapid decomposition of HA@Zn-TCPP,
releasing free TCPP for activating SDT. This controllable generation
of reactive oxygen species (ROS) could effectively decrease damage
to normal tissues. The HA@Zn-TCPP exhibited remarkable antitumor effects
in experiments, achieving a tumor inhibition rate of up to 82.1% when
under ultrasound. This finding provides an imperative strategy to
develop novel sonosensitizers for enhanced SDT.